학술논문
Post-COVID-19 Outcomes of Patients with Primary Glomerular Diseases: A Nationwide Controlled Study
Document Type
Report
Author
Ozturk, Savas; Karadag, Serhat; Ariel, Mustafa; Turkmen, Aydin; Turgutalp, Kenan; Aktas, Nimet; Kazancioglu, Rumeyza; Kuzu, Tolga; Ozturk, Ilyas; Aydin, Zeki; Ayar, Yavuz; Mutluay, Ruya; Ebinc, Fatma Ayerden; Pinar, Musa; Basturk, Taner; Yilmaz, Fatih; Inci, Ayca; Trabulus, Sinan; Ural, Zeynep; Pembegul, Irem; Azak, Alper; Palit, Fatih; Ergul, Metin; Alagoz, Selma; Safak, Seda; Akcali, Esra; Ulu, Sena; Gungor, Ozkan; Bakir, Elif Ari; Odabas, Ali Riza; Seyahi, Nurhan; Yildiz, Alaattin; Ates, Kenan
Source
Turkish Journal of Nephrology. April, 2024, Vol. 33 Issue 2, p179, 10 p.
Subject
Language
English
Abstract
Background: Patients with chronic diseases such as chronic kidney disease (CKD) have been reported to have more adverse outcomes during the coronavirus disease 2019 (COVID-19) pandemic. There are insufficient data on the outcomes of patients with primary glomerular diseases (PGD) after COVID-19. Methods: We designed a national multicenter observational study that included adult patients with biopsy-proven PGD who survived COVID-19. A control group was created from the same centers, including PGD patients without COVID-19. The clinical and laboratory data of the patients at baseline, first, and third months after COVID-19 were recorded. Results: A total of 129 patients from 21 centers were included (COVID-19 group, n = 77). Baseline characteristics were almost similar except the ratio of active disease in the non-COVID-19 group was significantly higher than in the COVID-19 group. No patients died during the first and third months. Respiratory symptoms were significantly higher in the COVID-19 group than in the non-COVID-19 group in the first month (7.8% vs. 0%, P = .039). All other follow-up outcomes, including initiation of chronic kidney replacement therapy and initiation of new immunosuppressive treatment, and the laboratory data were not different between the groups in the first and third months. Conclusion: Primary glomerular disease patients in the post-COVID-19 period had more respiratory symptoms than non-COVID-19 PGD patients, but outcomes, including death and initiation of kidney replacement therapy, were not different in the first and third months post COVID-19. Keywords: Chronic kidney disease, glomerulonephritis, outcome, post-COVID-19
INTRODUCTION Patients with chronic kidney disease (CKD) have been reported to have more adverse outcomes, including hospitalization, need for intensive care support, and mortality, during the coronavirus disease 2019 (COVID-19) [...]
INTRODUCTION Patients with chronic kidney disease (CKD) have been reported to have more adverse outcomes, including hospitalization, need for intensive care support, and mortality, during the coronavirus disease 2019 (COVID-19) [...]